论文部分内容阅读
鹅脱氧胆酸因对很多种动物都有肝毒性作用,故对其作为溶胆石药物而在治疗上是否安全的问题,迄今仍未确定。本文的研究目的是在使用鹅脱氧胆酸之前及其治疗期间,探索有关肝脏的结构和功能变化及其与胆汁中鹅脱氧胆酸或其异构体熊脱氧胆酸(Ursodeoxycholic acid)含量的关系。6例男性和2例女性胆石症病人,年龄38～72岁,体重57～104公斤,每日各口服鹅脱氧胆酸20毫克/公斤体重(此为以往其他学者所使用之剂量)。开始治疗前和以后每月测定血中酶活性以评价肝功能,包括谷草和谷丙转氨
Because of its hepatotoxic effects on many animal species, chenodeoxycholic acid has so far not been established as to whether it is safe to treat as a gallstone drug. The aim of this study was to investigate the changes in the structure and function of the liver and its relationship with the content of chenodeoxycholic acid or its isomer Ursodeoxycholic acid before and during treatment with chenodeoxycholic acid . 6 cases of male and 2 female patients with cholelithiasis, aged 38 to 72 years old, weighing 57 to 104 kg daily oral chenodeoxycholic acid 20 mg / kg body weight (this is the dose used by other scholars in the past). Blood enzyme activity was measured monthly before and after initiation of treatment to assess liver function including cereal and alanine